Valeant Pharmaceuticals Intl Stock Price, News & Analysis (NYSE:VRX)

$22.98 -0.86 (-3.61 %)
(As of 01/17/2018 02:13 AM ET)
Previous Close$23.84
Today's Range$22.88 - $24.37
52-Week Range$8.31 - $24.43
Volume14.89 million shs
Average Volume14.91 million shs
Market Capitalization$8.19 billion
P/E Ratio5.89
Dividend YieldN/A
Beta-0.22

About Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:VRX
CUSIPN/A
Phone+1-514-7446792

Debt

Debt-to-Equity Ratio4.84%
Current Ratio1.26%
Quick Ratio1.03%

Price-To-Earnings

Trailing P/E Ratio5.89230769230769
Forward P/E Ratio6.02
P/E Growth0.73

Sales & Book Value

Annual Sales$9.67 billion
Price / Sales0.83
Cash Flow$13.60 per share
Price / Cash1.69
Book Value$9.37 per share
Price / Book2.45

Profitability

Trailing EPS$3.90
Net Income$-2,409,000,000.00
Net Margins15.35%
Return on Equity51.56%
Return on Assets5.14%

Miscellaneous

Employees21,500
Outstanding Shares348,590,000

Valeant Pharmaceuticals Intl (NYSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals Intl's earnings last quarter?

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) issued its quarterly earnings data on Tuesday, November, 7th. The specialty pharmaceutical company reported $1.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.14. Valeant Pharmaceuticals Intl had a net margin of 15.35% and a return on equity of 51.56%. View Valeant Pharmaceuticals Intl's Earnings History.

Where is Valeant Pharmaceuticals Intl's stock going? Where will Valeant Pharmaceuticals Intl's stock price be in 2018?

19 analysts have issued 1 year price targets for Valeant Pharmaceuticals Intl's stock. Their forecasts range from $8.00 to $45.00. On average, they anticipate Valeant Pharmaceuticals Intl's share price to reach $18.50 in the next year. View Analyst Ratings for Valeant Pharmaceuticals Intl.

What are Wall Street analysts saying about Valeant Pharmaceuticals Intl stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals Intl stock:

  • 1. According to Zacks Investment Research, "After a tumultuous period, Valeant started a rebuilding process with its CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters. The company is also divesting Sprout Pharmaceuticals and ADDYI businesses. The weakness in the dermatology business was also a cause of concern given Valeant's dependence on the same. Although third-quarter 2017 results were encouraging, the company trimmed its guidance due to recent divestitures. Shares of the company have outperformed the industry in the last six months. However, we believe this might just not be enough to boost sentiment. " (1/13/2018)
  • 2. Cantor Fitzgerald analysts commented, "Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa, Florida." (8/16/2017)
  • 3. Royal Bank of Canada analysts commented, "We have revised our outlook due to the recent VRX financing and accounting treatment for Siliq revenues. While our revenue forecasts have increased due to Siliq, Adj. EBITDA forecasts have declined slightly. Following a modest increase in net debt, our price target declines to $18." (3/23/2017)
  • 4. Deutsche Bank AG analysts commented, "Lowered EPS on higher op ex, interest expense We updated our model following the company's 4Q results and 10-K filing, our meetings with management last week, and to reflect preliminary assumptions for the planned debt refinancing. Overall, we lowered our EPS estimates based primarily on higher spending and interest expense assumptions (see below), which reduced our DCF-derived PT to $19 (from $20). While our target implies material upside from the current stock price, we are sticking with our Hold rating pending greater visibility on improved demand trends for Xifaxan and other core assets, stabilization of the Dermatology business, and further steps to address the debt load and strengthen the balance sheet. We are encouraged that the company has begun to deliver on the expectations that it has set (as of 4Q), a theme we hope to see continue in the quarters ahead." (3/7/2017)
  • 5. Mizuho analysts commented, "The company is using its recently closed sale of assets to L'Oreal to repay $1.1B of a ~2.8% Term A loan due in 2018 (already excluded from our interest rate calculations). The company plans to refinance its existing credit agreement, issue new Term B loans that extend the maturity of current Term B loans due before 2022 (~$4.3B), issue new secured debt, and repay its remaining Term A loan due in April 2020 ($658M). Valeant also plans to repay a portion of its 6.75% secured debt due in 2018 (current balance is $1.59B). In tandem with this exercise, Valeant plans to relax its maintenance covenants in the revolver (currently $875M) and remove the covenants from its Term B loans. While the refinancing is not surprising, it reflects the cloudy outlook on future earnings, in our view." (3/6/2017)

Are investors shorting Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl saw a decrease in short interest in November. As of November 30th, there was short interest totalling 32,020,860 shares, a decrease of 21.7% from the November 15th total of 40,895,453 shares. Based on an average trading volume of 14,347,869 shares, the days-to-cover ratio is presently 2.2 days. Currently, 9.4% of the shares of the company are short sold.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer (Age 61)
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President (Age 61)
  • Christina Ackermann, Executive Vice President, General Counsel (Age 52)
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International (Age 55)
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology (Age 50)
  • Thomas W. Ross Sr, Lead Independent Director (Age 66)
  • Richard U. DeSchutter, Independent Director (Age 76)
  • Fredric N. Eshelman Ph.D., Independent Director (Age 68)
  • D. Robert Hale, Independent Director (Age 32)
  • Argeris N. Karabelas Ph.D., Independent Director (Age 64)

Who owns Valeant Pharmaceuticals Intl stock?

Valeant Pharmaceuticals Intl's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (1.04%), Hexavest Inc. (0.16%), Montrusco Bolton Investments Inc. (0.08%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Valeant Pharmaceuticals Intl stock include Argeris N Karabelas, John Paulson, Joseph C Papa, Paul Herendeen, Pershing Square Capital Manage, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Institutional Ownership Trends for Valeant Pharmaceuticals Intl.

Who sold Valeant Pharmaceuticals Intl stock? Who is selling Valeant Pharmaceuticals Intl stock?

Valeant Pharmaceuticals Intl's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for Valeant Pharmaceuticals Intl.

Who bought Valeant Pharmaceuticals Intl stock? Who is buying Valeant Pharmaceuticals Intl stock?

Valeant Pharmaceuticals Intl's stock was purchased by a variety of institutional investors in the last quarter, including Montrusco Bolton Investments Inc., Hexavest Inc. and Nisa Investment Advisors LLC. Company insiders that have bought Valeant Pharmaceuticals Intl stock in the last two years include Argeris N Karabelas, John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Insider Buying and Selling for Valeant Pharmaceuticals Intl.

How do I buy Valeant Pharmaceuticals Intl stock?

Shares of Valeant Pharmaceuticals Intl can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeant Pharmaceuticals Intl's stock price today?

One share of Valeant Pharmaceuticals Intl stock can currently be purchased for approximately $22.98.

How big of a company is Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl has a market capitalization of $8.19 billion and generates $9.67 billion in revenue each year. The specialty pharmaceutical company earns $-2,409,000,000.00 in net income (profit) each year or $3.90 on an earnings per share basis. Valeant Pharmaceuticals Intl employs 21,500 workers across the globe.

How can I contact Valeant Pharmaceuticals Intl?

Valeant Pharmaceuticals Intl's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792 or via email at [email protected]


MarketBeat Community Rating for Valeant Pharmaceuticals Intl (VRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  1,127 (Vote Outperform)
Underperform Votes:  1,041 (Vote Underperform)
Total Votes:  2,168
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Valeant Pharmaceuticals Intl (NYSE:VRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.112.052.052.05
Ratings Breakdown: 4 Sell Rating(s)
9 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
12 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
12 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.50$17.61$17.89$16.89
Price Target Upside: 22.40% downside10.51% downside24.10% upside2.74% downside

Valeant Pharmaceuticals Intl (NYSE:VRX) Consensus Price Target History

Price Target History for Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl (NYSE:VRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018HC WainwrightBoost Price TargetBuy$17.00 -> $24.00HighView Rating Details
1/5/2018TD SecuritiesBoost Price TargetBuy$20.00 -> $27.00HighView Rating Details
1/4/2018Wells Fargo & CoReiterated RatingSellLowView Rating Details
1/1/2018Cantor FitzgeraldSet Price TargetBuy$25.00HighView Rating Details
12/15/2017MizuhoBoost Price TargetUnderperform -> Underperform$7.00 -> $10.00MediumView Rating Details
12/14/2017JPMorgan Chase & Co.DowngradeNeutral -> Underweight$12.00HighView Rating Details
12/3/2017Deutsche BankSet Price TargetHold$18.00LowView Rating Details
11/13/2017BMO Capital MarketsBoost Price TargetMarket Perform$16.00 -> $17.00N/AView Rating Details
11/10/2017Piper Jaffray CompaniesReiterated RatingSell$12.00N/AView Rating Details
11/8/2017Royal Bank of CanadaSet Price TargetSector Perform$18.00N/AView Rating Details
10/3/2017Canaccord GenuityReiterated RatingHold$16.00LowView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$45.00MediumView Rating Details
8/10/2017Rodman & RenshawReiterated RatingNeutral$17.00HighView Rating Details
8/10/2017Jefferies GroupReiterated RatingBuy$18.00HighView Rating Details
8/9/2017ScotiabankBoost Price TargetSector Perform$14.00 -> $16.00MediumView Rating Details
6/17/2017GuggenheimInitiated CoverageBuy$18.00HighView Rating Details
5/23/2017BarclaysReiterated RatingHold$20.00LowView Rating Details
5/10/2017BTIG ResearchReiterated RatingNeutralMediumView Rating Details
3/11/2017Morgan StanleyReiterated RatingEqual Weight$17.00 -> $12.00N/AView Rating Details
5/29/2016Susquehanna BancsharesReiterated RatingHold$105.00N/AView Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/1/2016CitigroupReiterated RatingBuyN/AView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00N/AView Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Valeant Pharmaceuticals Intl (NYSE:VRX) Earnings History and Estimates Chart

Earnings by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl (NYSE VRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017$0.90$1.04ViewN/AView Earnings Details
8/8/20176/30/2017$0.97$1.05$2.23 billion$2.23 billionViewListenView Earnings Details
5/9/20173/31/2017$0.87$2.80$2.17 billion$2.11 billionViewListenView Earnings Details
2/28/2017Q416$1.20$1.26$2.34 billion$2.40 billionViewListenView Earnings Details
11/8/2016Q316$1.78$1.55$2.49 billion$2.48 billionViewListenView Earnings Details
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
2/27/2012Q4 2011$0.85$0.90ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
11/4/2010Q3 2010$0.34($0.28)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.26$0.35ViewN/AView Earnings Details
5/6/2010Q1 2010$0.27$0.54ViewN/AView Earnings Details
2/25/2010Q4 2009$0.40$0.56ViewN/AView Earnings Details
11/5/2009Q3 2009$0.42$0.32ViewN/AView Earnings Details
8/6/2009Q2 2009$0.34$0.34ViewN/AView Earnings Details
5/6/2009Q1 2009$0.30$0.41ViewN/AView Earnings Details
2/26/2009Q4 2008$0.30$0.34ViewN/AView Earnings Details
11/6/2008Q3 2008$0.27$0.35ViewN/AView Earnings Details
8/13/2008Q2 2008$0.34$0.37ViewN/AView Earnings Details
5/8/2008Q1 2008$0.41$0.43ViewN/AView Earnings Details
3/13/2008Q4 2007$0.39$0.45ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Valeant Pharmaceuticals Intl (NYSE:VRX) Earnings Estimates

Current Year EPS Consensus Estimate: $3.82 EPS
Next Year EPS Consensus Estimate: $3.44 EPS

Dividends

Dividend History for Valeant Pharmaceuticals Intl (NYSE:VRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Valeant Pharmaceuticals Intl (NYSE VRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.87%
Institutional Ownership Percentage: 49.45%
Insider Trades by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)
Institutional Ownership by Quarter for Valeant Pharmaceuticals Intl (NYSE:VRX)

Valeant Pharmaceuticals Intl (NYSE VRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2017John PaulsonDirectorBuy344,216$14.40$4,956,710.4094,559View SEC Filing  
8/21/2017Schutter Richard U DeDirectorBuy10,000$14.33$143,300.0077,479View SEC Filing  
5/11/2017Schutter Richard U DeDirectorBuy20,000$13.90$278,000.0070,572View SEC Filing  
3/15/2017Schutter Richard U DeDirectorBuy10,000$10.80$108,000.0025,190View SEC Filing  
3/14/2017Paul HerendeenCFOBuy24,000$10.72$257,280.00174,000View SEC Filing  
3/14/2017Valueact Capital Master Fund,InsiderBuy3,000,000$10.82$32,460,000.00View SEC Filing  
3/13/2017Pershing Square Capital ManageDirectorSell18,114,432$11.00$199,258,752.00View SEC Filing  
12/14/2016Thomas W Sr. RossDirectorBuy5,000$14.73$73,650.0026,822View SEC Filing  
12/12/2016Pershing Square Capital ManageDirectorSell3,476,690$14.85$51,628,846.50View SEC Filing  
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.0020,726View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.002,442,199View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.0015,532View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.0023,999View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00137,495View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.5753,582View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00147,206View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.4028,390View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00152,206View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.274,025,498View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.0016,500View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.0027,808View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.008,500View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00167,282View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.0053,969View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.0026,057View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60188,277View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.0032,156View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.007,500View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Valeant Pharmaceuticals Intl (NYSE VRX) News Headlines

Source:
DateHeadline
Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, ValeantJudge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, Valeant
www.wsj.com - January 16 at 5:16 PM
[$$] Judge Signals He Will Approve Settlement Between Allergan Shareholders and Pershing, Valeant[$$] Judge Signals He Will Approve Settlement Between Allergan Shareholders and Pershing, Valeant
finance.yahoo.com - January 16 at 5:16 PM
Getting Warmer? Valeants Pipeline, Reduced Debt Make It Less Risky…But Not a BuyGetting Warmer? Valeant's Pipeline, Reduced Debt Make It Less Risky…But Not a Buy
finance.yahoo.com - January 16 at 4:19 PM
What’s Teva Pharmaceutical’s Research and Development Strategy?What’s Teva Pharmaceutical’s Research and Development Strategy?
finance.yahoo.com - January 16 at 10:37 AM
Valeant Pharmaceuticals Intl (VRX) Given Hold Rating at HC WainwrightValeant Pharmaceuticals Intl (VRX) Given Hold Rating at HC Wainwright
www.americanbankingnews.com - January 16 at 8:08 AM
Valeant Pharmaceuticals Intl Inc (VRX) Receives Average Rating of "Hold" from BrokeragesValeant Pharmaceuticals Intl Inc (VRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 15 at 4:36 AM
Zacks: Brokerages Expect Valeant Pharmaceuticals Intl Inc (VRX) Will Post Quarterly Sales of $2.16 BillionZacks: Brokerages Expect Valeant Pharmaceuticals Intl Inc (VRX) Will Post Quarterly Sales of $2.16 Billion
www.americanbankingnews.com - January 15 at 2:02 AM
$0.97 EPS Expected for Valeant Pharmaceuticals Intl Inc (VRX) This Quarter$0.97 EPS Expected for Valeant Pharmaceuticals Intl Inc (VRX) This Quarter
www.americanbankingnews.com - January 13 at 11:32 PM
Valeant Pharmaceuticals Intl (VRX) Downgraded to "Strong Sell" at Zacks Investment ResearchValeant Pharmaceuticals Intl (VRX) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - January 13 at 12:28 PM
Valeant (VRX) Division Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In LotionValeant (VRX) Division Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion
www.streetinsider.com - January 12 at 4:14 PM
From Zit to Zip: Valeant Rises on Acne Drug ApplicationFrom Zit to Zip: Valeant Rises on Acne Drug Application
finance.yahoo.com - January 12 at 4:14 PM
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion FormOrtho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
finance.yahoo.com - January 12 at 9:39 AM
Bill Ackman slashes the annual management fee for Pershing Square hedge fundBill Ackman slashes the annual management fee for Pershing Square hedge fund
finance.yahoo.com - January 11 at 4:27 PM
Could Valeant Pharmaceuticals Intl Inc. Be the Rebound Stock of the Year?Could Valeant Pharmaceuticals Intl Inc. Be the Rebound Stock of the Year?
www.fool.ca - January 11 at 9:52 AM
Today’s Research Reports on Trending Tickers: Sarepta Therapeutics and Valeant PharmaceuticalsToday’s Research Reports on Trending Tickers: Sarepta Therapeutics and Valeant Pharmaceuticals
finance.yahoo.com - January 11 at 9:52 AM
Valeant CEO Is in the Midst of the ‘Turnaround Opportunity of a Lifetime’Valeant CEO Is in the Midst of the ‘Turnaround Opportunity of a Lifetime’
finance.yahoo.com - January 10 at 4:21 PM
Valeant CEO: Drugmaker Knee-Deep in Turnaround Effort of a LifetimeValeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'
finance.yahoo.com - January 10 at 4:21 PM
How Valeant Position Affected Pershing Square Capital ManagementHow Valeant Position Affected Pershing Square Capital Management
finance.yahoo.com - January 9 at 5:22 PM
Valeant on the Street: Analyst Recommendations in December 2017Valeant on the Street: Analyst Recommendations in December 2017
finance.yahoo.com - January 9 at 5:22 PM
Valeant CEO looks to boost performance with price hikes and seven key productsValeant CEO looks to boost performance with price hikes and seven key products
finance.yahoo.com - January 9 at 5:22 PM
Valeant Pharmaceuticals' Stellar 43% Gain in 2017, ExplainedValeant Pharmaceuticals' Stellar 43% Gain in 2017, Explained
finance.yahoo.com - January 9 at 4:23 PM
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare ConferenceValeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 9 at 9:34 AM
How Did Valeant’s Branded Rx Segment Perform in 3Q17?How Did Valeant’s Branded Rx Segment Perform in 3Q17?
finance.yahoo.com - January 8 at 9:55 AM
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy SystemBausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite™ Vision Enhancement System, Including The Vitesse™ Vitrectomy System
finance.yahoo.com - January 8 at 9:55 AM
A Post-3Q17 Update on Key Valeant Branded Drugs: Xifaxan, Apriso, and GlumetzaA Post-3Q17 Update on Key Valeant Branded Drugs: Xifaxan, Apriso, and Glumetza
finance.yahoo.com - January 8 at 9:55 AM
Valeant Pharmaceuticals Intl Inc’s (VRX) Bausch + Lomb Scores CE Mark for Ophthalmic Surgical PlatformValeant Pharmaceuticals Intl Inc’s (VRX) Bausch + Lomb Scores CE Mark for Ophthalmic Surgical Platform
finance.yahoo.com - January 8 at 9:55 AM
Valeant Pharmaceuticals Intl (VRX) Given New $27.00 Price Target at TD SecuritiesValeant Pharmaceuticals Intl (VRX) Given New $27.00 Price Target at TD Securities
www.americanbankingnews.com - January 5 at 6:28 PM
Some Valeant shareholders swap stakes for ones in female libido drugSome Valeant shareholders swap stakes for ones in female libido drug
finance.yahoo.com - January 5 at 3:57 PM
How Did Valeant Pharmaceuticals Perform in 3Q17?How Did Valeant Pharmaceuticals Perform in 3Q17?
finance.yahoo.com - January 5 at 9:40 AM
How Valeant Subsidiary Bausch + Lomb Performed in 3Q17How Valeant Subsidiary Bausch + Lomb Performed in 3Q17
finance.yahoo.com - January 5 at 9:40 AM
Valeant: Positive Catalysts Kick Off New Year - Seeking AlphaValeant: Positive Catalysts Kick Off New Year - Seeking Alpha
seekingalpha.com - January 4 at 10:32 AM
Will Court Force Valeant, Ackman To Disgorge $2 Billion Of Insider Trading Profits? - Seeking AlphaWill Court Force Valeant, Ackman To Disgorge $2 Billion Of Insider Trading Profits? - Seeking Alpha
seekingalpha.com - January 4 at 10:32 AM
Pershing Square, Valeant Ordered to Defend Allergan SettlementPershing Square, Valeant Ordered to Defend Allergan Settlement
finance.yahoo.com - January 4 at 9:31 AM
Pershing Square, Valeant to appear in court on insider trading suit settlementPershing Square, Valeant to appear in court on insider trading suit settlement
www.reuters.com - January 3 at 8:44 AM
Bill Ackman’s Allergan Insider-Trading Dispute Doesn’t Look BadBill Ackman’s Allergan Insider-Trading Dispute Doesn’t Look Bad
finance.yahoo.com - January 3 at 8:44 AM
Valeant (VRX) to Settle Allergan Litigation for $290 MillionValeant (VRX) to Settle Allergan Litigation for $290 Million
finance.yahoo.com - January 3 at 8:44 AM
Valeant To Present At The 36th Annual J.P. Morgan Healthcare ConferenceValeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 8:44 AM
Pershing Square, Valeant asked to appear for hearing on insider trading suitPershing Square, Valeant asked to appear for hearing on insider trading suit
finance.yahoo.com - January 2 at 11:41 PM
Valeant, Ackman Settle Insider Trading Lawsuit For $290 Million - Seeking AlphaValeant, Ackman Settle Insider Trading Lawsuit For $290 Million - Seeking Alpha
seekingalpha.com - January 2 at 10:06 PM
"Fast Money" final trades: WMT, VRX and more"Fast Money" final trades: WMT, VRX and more
finance.yahoo.com - January 2 at 6:39 PM
FY2018 EPS Estimates for Valeant Pharmaceuticals Intl Inc (VRX) Reduced by AnalystFY2018 EPS Estimates for Valeant Pharmaceuticals Intl Inc (VRX) Reduced by Analyst
www.americanbankingnews.com - December 30 at 6:34 PM
 Brokerages Anticipate Valeant Pharmaceuticals Intl Inc (VRX) Will Announce Quarterly Sales of $2.16 Billion Brokerages Anticipate Valeant Pharmaceuticals Intl Inc (VRX) Will Announce Quarterly Sales of $2.16 Billion
www.americanbankingnews.com - December 30 at 5:38 PM
Valeant Pharmaceuticals Intl (VRX) Rating Lowered to Buy at VetrValeant Pharmaceuticals Intl (VRX) Rating Lowered to Buy at Vetr
www.americanbankingnews.com - December 30 at 10:34 AM
Cantor Fitzgerald Analysts Give Valeant Pharmaceuticals Intl (VRX) a $25.00 Price TargetCantor Fitzgerald Analysts Give Valeant Pharmaceuticals Intl (VRX) a $25.00 Price Target
www.americanbankingnews.com - December 29 at 11:34 PM
Pershing Square and Valeant reach agreement on settlement splitPershing Square and Valeant reach agreement on settlement split
finance.yahoo.com - December 29 at 4:18 PM
Valeant Pharmaceuticals International (VRX) a Buy on Healthy Earnings Visibility - Investorplace.comValeant Pharmaceuticals International (VRX) a Buy on Healthy Earnings Visibility - Investorplace.com
www.investorplace.com - December 29 at 10:05 AM
ETFs with exposure to Valeant Pharmaceuticals International, Inc. : December 26, 2017ETFs with exposure to Valeant Pharmaceuticals International, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 8:18 PM
Valeant: Better and Better?Valeant: Better and Better?
finance.yahoo.com - December 26 at 8:18 PM
Valeant Pharmaceuticals Intl (VRX) Raised to "Strong-Buy" at VetrValeant Pharmaceuticals Intl (VRX) Raised to "Strong-Buy" at Vetr
www.americanbankingnews.com - December 25 at 6:28 PM
Valeant Pharmaceuticals International, Inc. :VRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Valeant Pharmaceuticals International, Inc. :VRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 5:31 PM

SEC Filings

Valeant Pharmaceuticals Intl (NYSE:VRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Valeant Pharmaceuticals Intl (NYSE:VRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Valeant Pharmaceuticals Intl (NYSE VRX) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.